Latest News

The Katz Laboratory in the Department of Pathology at Yale School of Medicine seeks applicants for an open Postdoctoral position.

Faculty and staff of Yale Pathology went to the Water’s Edge Resort in Madison on April 2 for a full-day retreat, the department’s first in-person gathering since the coronavirus pandemic began more than two years ago.

Pathologists and research scientists from Department of Pathology at Yale School of Medicine will be involved in more than 40 presentations and sessions at the United States and Canadian Academy of Pathology (USCAP) 2022 Annual Meeting in Los Angeles March 19-24.

A new Yale study reveals that astrocytes, a type of glial cell found in the central nervous system, develop at different rates in male and female mice, differences that could affect how neural networks are constructed and may have implications for disease risk. The findings were published Feb. 1 in Cell Reports.

Scientists based at Yale University have been using multiplexed error robust fluorescence in situ hybridization (MERFISH) to investigate the spatial transcriptome profiles of individual cells in intact tissue.

Congratulations to Samuel Kerr for Receiving the NIH F31 NRSA Fellowship!

The battle against cancer is increasingly being fought on the genetic level, and Dr. Samuel Katz is aiding the body’s immune system by creating safer, more effective weapons. His research is focused on treating cancers of the blood, such as multiple myeloma, Hodgkin’s lymphoma and acute myeloid leukemia, but his technique could eventually be used against solid tumors as well, including cancers of the breast, ovary, pancreas and colon. Most gene therapy uses genetically modified DNA in the body’s T lymphocytes — a type of white blood cell that is an integral part of the body’s immune system — to find, attack and kill cancer cells.

Support from ACGT has Dr. Samuel Katz at Yale School of Medicine refining the current research. He is reprogramming cells, with RNA, the genetic material that delivers the message, to destroy the cancerous ones — acting as soldiers in battle, if you will. “We give them the message,” says Dr. Katz, “and then the message goes away, and when the soldier is done with his job he returns back to normal.” If successful, this approach will make safer and stronger cells – a super-soldier that reintegrates into society when the war is won.